Dactolisib Reduced RTIs in Older Asthma Patients

In a Phase 2 trial, Dactolisib (RTB101), a TORC1 inhibitor, was well tolerated and reduced the incidence of respiratory tract infections in adults age 65 and older, particularly those with asthma.